Skip to content

Study · Randomized controlled trial · n = 104 · 2007

5 results

GnRH antagonist-induced inhibition of the premature LH surge increases pregnancy rates in IUI-stimulated cycles. A prospective randomized trial.

Allegra A, Marino A, Coffaro F, Scaglione P, Sammartano F, Rizza G, Volpes A

Human reproduction (Oxford, England)10 Oct 2006Cited by 51 (Europe PMC)

PMID17032732 (opens in a new tab)DOI10.1093/humrep/del337 (opens in a new tab)PepBankPUB-17032732
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In COS/IUI patients, pregnancy per patient was higher with cetrorelix plus rFSH than rFSH alone: 53.8% versus 30.8% (P = 0.017).

    In plain wordsIn COS/IUI patients, pregnancy per patient was higher with cetrorelix plus rFSH than rFSH alone: 53.8% versus 30.8%.

    Peptide
    Cetrorelix
    Outcome
    IncreaseClinical pregnancy rate per patient
    Study

    n = 104

    Comparator
    rFSH alone
    Analysis
    Primary
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Measurements

    Clinical pregnancy rate per patient
    53.8%
    group A, rFSH plus cetrorelix
    Clinical pregnancy rate per patient
    30.8%
    group B, rFSH alone

    Source sentences

    Summary
    The pregnancy rate per patient was 53.8% in group A and 30.8% in group B (P = 0.017).
    2 context sentences
    Summary · context
    The primary outcome measure was clinical pregnancy rate per couple.
    Summary · context
    A total of 104 patients were randomly divided, using a randomization list, into two groups: in group A (n = 52), recombinant FSH (rFSH) was given with GnRH antagonist Cetrorelix, and in group B (n = 52), the patients received rFSH alone in a manner similar to that of group A.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In COS/IUI patients, premature LH surge was lower with cetrorelix plus rFSH than rFSH alone: 7% versus 35% (P < 0.0001).

    In plain wordsIn COS/IUI patients, premature LH surge was lower with cetrorelix plus rFSH than rFSH alone: 7% versus 35%.

    Peptide
    Cetrorelix
    Outcome
    DecreasePremature LH surge
    Study

    n = 104

    Comparator
    rFSH alone
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Measurements

    Premature LH surge rate
    7%
    group A, rFSH plus cetrorelix
    Premature LH surge rate
    35%
    group B, rFSH alone

    Source sentences

    Summary
    The rate of premature LH surge was 7% in group A and 35% in group B (P < 0.0001).
    1 context sentence
    Summary · context
    A total of 104 patients were randomly divided, using a randomization list, into two groups: in group A (n = 52), recombinant FSH (rFSH) was given with GnRH antagonist Cetrorelix, and in group B (n = 52), the patients received rFSH alone in a manner similar to that of group A.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In COS/IUI patients, LH was lower with cetrorelix plus rFSH: 3.3 +/- 3.3 versus 9.9 +/- 7.9 mIU/ml with rFSH alone (P < 0.0001).

    In plain wordsIn COS/IUI patients, LH was lower with cetrorelix plus rFSH than rFSH alone.

    Peptide
    Cetrorelix
    Outcome
    DecreaseLH concentration
    Study

    n = 104

    Comparator
    rFSH alone
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Measurements

    LH concentration
    3.3 mIU/ml
    group A, rFSH plus cetrorelix (reported +/- 3.3)
    LH concentration
    9.9 mIU/ml
    group B, rFSH alone (reported +/- 7.9)

    Source sentences

    Summary
    The mean values of LH and progesterone were significantly lower in patients receiving GnRH antagonist than in those who did not (3.3 +/- 3.3 mIU/ml in group A versus 9.9 +/- 7.9 mIU/ml in group B, P < 0.0001, for LH;
    1 context sentence
    Summary · context
    A total of 104 patients were randomly divided, using a randomization list, into two groups: in group A (n = 52), recombinant FSH (rFSH) was given with GnRH antagonist Cetrorelix, and in group B (n = 52), the patients received rFSH alone in a manner similar to that of group A.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In COS/IUI patients, progesterone was lower with cetrorelix plus rFSH: 1.3 +/- 1.1 versus 2.1 +/- 1.9 ng/ml with rFSH alone (P < 0.0001).

    In plain wordsIn COS/IUI patients, progesterone was lower with cetrorelix plus rFSH than rFSH alone.

    Peptide
    Cetrorelix
    Outcome
    DecreaseProgesterone concentration
    Study

    n = 104

    Comparator
    rFSH alone
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Measurements

    Progesterone concentration
    1.3 ng/ml
    group A, rFSH plus cetrorelix (SD 1.1)
    Progesterone concentration
    2.1 ng/ml
    group B, rFSH alone (SD 1.9)

    Source sentences

    Summary
    1.3 +/- 1.1 ng/ml versus 2.1 +/- 1.9 ng/ml for group A and B, respectively, P < 0.0001, for progesterone).
    1 context sentence
    Summary · context
    A total of 104 patients were randomly divided, using a randomization list, into two groups: in group A (n = 52), recombinant FSH (rFSH) was given with GnRH antagonist Cetrorelix, and in group B (n = 52), the patients received rFSH alone in a manner similar to that of group A.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In COS/IUI cycles, premature luteinization occurred in 2/144 (1.4%) with cetrorelix plus rFSH versus 16/154 (10.4%) with rFSH alone (P = 0.001).

    In plain wordsIn COS/IUI cycles, premature luteinization was lower with cetrorelix plus rFSH than rFSH alone: 1.4% versus 10.4%.

    Peptide
    Cetrorelix
    Outcome
    DecreasePremature luteinization
    Study

    n: not reported in source

    Comparator
    rFSH alone
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Measurements

    Premature luteinization
    1.4%
    group A, 2 of 144 cycles
    Premature luteinization
    10.4%
    group B, 16 of 154 cycles

    Source sentences

    Summary
    A premature luteinization was observed in two cycles of 144 in group A (1.4%) and in 16 cycles of 154 in group B (10.4%) (P = 0.001).
    1 context sentence
    Summary · context
    A total of 104 patients were randomly divided, using a randomization list, into two groups: in group A (n = 52), recombinant FSH (rFSH) was given with GnRH antagonist Cetrorelix, and in group B (n = 52), the patients received rFSH alone in a manner similar to that of group A.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.